

A multidisciplinary forum: How can we improve management of hormone-sensitive prostate cancer?

Industry session by FERRING PHARMACEUTICALS

Sunday, 26 March
17:45 - 19:15

Location: Room Vienna, North Hall (Level 1)

Chair: A. Briganti, Milan (IT)

Aims and objectives of this session

- A multidisciplinary panel of clinicians will share best practice around the current place of androgen deprivation therapy (ADT) in the treatment of hormone-sensitive prostate cancer across the different stages of the disease
 - – To include treatment adjuvant to surgery and radiation
 - – In combination with chemotherapy
- Highlight the differences in mechanism of action and compare efficacy and safety profiles of different ADT agents
- Discuss future directions in hormonal treatment of prostate cancer

17:45 - 17:50

Welcome and introduction

A. Briganti, Milan (IT)

17:50 - 18:07

The role of (neo) adjuvant hormonal treatment with surgery for localised high-risk and locally-advanced prostate cancer

A. Briganti, Milan (IT)

18:07 - 18:24

Combining radiation therapy and androgen deprivation for intermediate- and high-risk prostate cancer - A critical review

H. Payne, London (GB)

18:24 - 18:41

Hormonal therapies are not all the same: Role of antagonists vs agonists

A.S. Merseburger, Lübeck (DE)

18:41 - 18:58

ADT & cardiovascular risks: Current evidence and future research

D.J. Rosario, Sheffield (GB)

18:58 - 19:15

Panel discussion on future treatment directions